LifeVest Wearable Defibrillator Prescribed by Physicians at All U.S. News and World Report’s #1 Ranked “Top Metro” Hospitals
CHELMSFORD, Mass.--(BUSINESS WIRE)-- ZOLL Medical Corporation (Nasdaq GS: ZOLL) announced today that more than 40,000 patients at high risk of sudden cardiac arrest (SCA) have been prescribed the LifeVest® Wearable Defibrillator. It was also reported that physicians at all of the “Top Metro” hospitals designated by U.S. News and World Report as the number one hospital in each of 52 metropolitan areas have prescribed the LifeVest for patients.
The LifeVest is worn by patients at risk for SCA, providing protection during their changing condition and while permanent risk for SCA has not been established. The LifeVest allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart. If a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
“The fact that these two significant milestones occurred simultaneously indicates the growing adoption of the LifeVest by leading physicians in their treatment protocol for patients at risk of SCA,” said Richard A. Packer, Chief Executive Officer of ZOLL.
The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.
The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.
For more information, go to www.zoll.com or call 1-800-543-3267.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, our belief regarding revenues, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010 and updated in the Company’s Quarterly Reports on Form 10-Q filed subsequently to the Form 10-K. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.
CONTACT:
INVESTOR CONTACT:
ZOLL Medical Corporation
Ernest Whiton, +1 978-421-9655
Chief Financial Officer
or
MEDIA CONTACT:
ZOLL Medical Corporation
Diane Egan, +1 978-421-9637
[email protected]
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Cardiology Hospitals Medical Devices Other Health General Health
MEDIA:
| Logo |